Exposure to aromatic amines may occur via tobacco smoke, hair dyes or tattoo inks, but also in the workplace during certain manufacturing processes. As some aromatic amines are known or suspected carcinogens, human biomonitoring (HBM) is essential to assess their exposure. Aromatic amines were among the selected chemicals in HBM4EU, a European-wide project to harmonise and advance HBM within 30 European countries. For this purpose, the analytical comparability and accuracy of participating laboratories were assessed by a QA/QC programme comprising interlaboratory comparison investigations (ICIs) and external quality assurance schemes (EQUASs). This paper presents the evaluation process and discusses the results of three ICI/EQUAS rounds for the determination of aromatic amines in urine conducted in 2019 and 2020. The final evaluation included ten participants which analysed the following six targeted aromatic amines over three rounds: aniline, ortho-toluidine (TOL), 4,4'-methylenedianiline (MDA), 4,4'-methylenebis(2-chloroaniline) (MOCA), 2,4-diaminotoluene (2,4-TDA), and 2,6-diaminotoluene (2,6-TDA). Most participants achieved satisfactory and highly comparable results, although low quantification limits were required to quantify the parameters at the level of exposure in the general population. Hydrolysis of the sample followed by liquid-liquid extraction and subsequent analysis of the derivatised analytes by means of GC-MS/MS were preferred for the sensitive and precise determination of aromatic amines in urine. This QA/QC programme succeeded in establishing a network of laboratories with high analytical comparability and accuracy for the analysis of aromatic amines in Europe.

• MeSH
• aminy * moč   analýza   MeSH
• aniliny moč   MeSH
• biologický monitoring * metody   MeSH
• fenylendiaminy MeSH
• laboratoře normy   MeSH
• lidé MeSH
• methylenbis(chloranilin) MeSH
• řízení kvality MeSH
• tandemová hmotnostní spektrometrie metody   MeSH
• toluidiny MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• srovnávací studie MeSH
• Geografické názvy
• Evropa MeSH
• Názvy látek
• 2-toluidine MeSH Prohlížeč
• 2,4-diaminotoluene MeSH Prohlížeč
• 4,4'-diaminodiphenylmethane MeSH Prohlížeč
• aminy * MeSH
• aniline MeSH Prohlížeč
• aniliny MeSH
• fenylendiaminy MeSH
• methylenbis(chloranilin) MeSH
• toluidiny MeSH

The potential of microRNAs to protect the female reproductive system from the toxic influence of oil-related environmental contaminants has not yet been examined. The aim of the present study was to examine the ability of the microRNA miR-152 to prevent the toxic effects of toluene on ovarian cells. Porcine ovarian granulosa cells transfected or not transfected with miR-152 mimics were cultured with or without toluene (0, 10 and 100 ng/ml). The expression of miR-152; cell viability; proliferation (accumulation of PCNA, cyclin B1 and BrdU); cytoplasmic/mitochondrial apoptosis (accumulation of bax and caspase 3); and release of progesterone, testosterone and estradiol were quantified via RT-qPCR, the Trypan blue exclusion test, quantitative immunocytochemistry, the BrdU assay and ELISA. The addition of toluene reduced cell viability, decreased the levels of all the measured markers of proliferation and the release of all the measured steroid hormones, and promoted the expression of apoptosis markers. Transfection of cells with miR-152 mimics increased the expression of miR-152, cell proliferation, and progesterone release but reduced apoptosis and the release of testosterone and estradiol. Moreover, miR-152 prevented or inhibited all the toluene effects in addition to its inhibitory effect on testosterone and estradiol release. The present results demonstrate that miR-152 can protect ovarian cells from the harmful influence of toluene.

• MeSH
• apoptóza * účinky léků   MeSH
• estradiol MeSH
• folikulární buňky * účinky léků   metabolismus   MeSH
• kultivované buňky MeSH
• mikro RNA * metabolismus   genetika   MeSH
• prasata MeSH
• progesteron metabolismus   MeSH
• proliferace buněk účinky léků   MeSH
• toluen * toxicita   MeSH
• viabilita buněk účinky léků   MeSH
• zvířata MeSH
• Check Tag
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• estradiol MeSH
• mikro RNA * MeSH
• progesteron MeSH
• toluen * MeSH

BACKGROUND: Evobrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown preliminary efficacy in people with relapsing multiple sclerosis in a phase 2 trial. Here, we aimed to compare the safety and efficacy of evobrutinib with the active comparator teriflunomide in people with relapsing multiple sclerosis. METHODS: EvolutionRMS1 and evolutionRMS2 were two multicentre, randomised, double-blind, double-dummy, active-controlled, phase 3 trials conducted at 701 multiple sclerosis centres and neurology clinics in 52 countries. Adults aged 18-55 years with relapsing multiple sclerosis (Expanded Disability Status Scale [EDSS] score of 0·0-5·5) were included. Participants were randomly assigned (1:1) using a central interactive web response system to receive either evobrutinib (45 mg twice per day with placebo once per day) or teriflunomide (14 mg once per day with placebo twice per day), all taken orally and in an unfasted state, with randomisation stratified by geographical region and baseline EDSS. All study staff and participants were masked to the study interventions. The primary endpoint for each study was annualised relapse rate based on adjudicated qualified relapses up to 156 weeks, assessed in the full analysis set (defined as all randomly assigned participants) with a negative binomial model. These studies are registered with ClinicalTrials.gov (NCT04338022 for evolutionRMS1 and NCT04338061 for evolutionRMS2, both are terminated). FINDINGS: The primary analysis was done using data for 2290 randomly assigned participants collected from June 12, 2020, to Oct 2, 2023. 1124 participants were included in the full analysis set in evolutionRMS1 (560 in the evobrutinib group and 564 in the teriflunomide group) and 1166 in evolutionRMS2 (583 in each group). 751 (66·8%) participants were female and 373 (33·1%) were male in evolutionRMS1, whereas 783 (67·2%) were female and 383 (32·8%) were male in evolutionRMS2. Annualised relapse rate was 0·15 (95% CI 0·12-0·18 with evobrutinib vs 0·14 [0·11-0·18] with teriflunomide (adjusted RR 1·02 [0·75-1·39]; p=0·55) in evolutionRMS1 and 0·11 (0·09-0·13 vs 0·11 [0·09-0·13]; adjusted RR 1·00 [0·74-1·35]; p=0·51) in evolutionRMS2. The pooled proportion of participants with any treatment-emergent adverse event (TEAE) was similar between treatment groups (976 [85·6%] of 1140 with evobrutinib vs 999 [87·2%] of 1146 with teriflunomide). The most frequently reported TEAEs were COVID-19 (223 [19·6%] with evobrutinib vs 223 [19·5%] with teriflunomide), alanine aminotransferase increased (173 [15·2%] vs 204 [17·8%]), aspartate aminotransferase increased (110 [9·6%] vs 131 [11·4%]), and headache (175 [15·4%] vs 176 [15·4%]). Serious TEAE incidence rates were higher with evobrutinib than teriflunomide (86 [7·5%] vs 64 [5·6%]). Liver enzyme elevations at least 5 × upper limit of normal were more common with evobrutinib than with teriflunomide, particularly in the first 12 weeks (55 [5·0%] vs nine [<1%]). Three people who received evobrutinib and one who received teriflunomide met the biochemical definition of Hy's law; all cases resolved after discontinuation of treatment. There were two deaths (one in each group), neither related to study treatment. INTERPRETATION: The efficacy of evobrutinib was not superior to that of teriflunomide. Together, efficacy and liver-related safety findings do not support the use of evobrutinib in people with relapsing multiple sclerosis. FUNDING: Merck.

• MeSH
• dospělí MeSH
• dvojitá slepá metoda MeSH
• hydroxybutyráty * MeSH
• inhibitory proteinkinas terapeutické užití   škodlivé účinky   MeSH
• krotonáty * terapeutické užití   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• nitrily * terapeutické užití   MeSH
• piperidiny MeSH
• proteinkinasa BTK antagonisté a inhibitory   MeSH
• pyrimidiny * terapeutické užití   MeSH
• relabující-remitující roztroušená skleróza * farmakoterapie   MeSH
• toluidiny * terapeutické užití   MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze III MeSH
• multicentrická studie MeSH
• randomizované kontrolované studie MeSH
• Názvy látek
• evobrutinib MeSH Prohlížeč
• hydroxybutyráty * MeSH
• inhibitory proteinkinas MeSH
• krotonáty * MeSH
• nitrily * MeSH
• piperidiny MeSH
• proteinkinasa BTK MeSH
• pyrimidiny * MeSH
• teriflunomide MeSH Prohlížeč
• toluidiny * MeSH

Two cost-effective packing materials were used for n-butyl acetate removal in lab-scale biofilters, namely waste spruce root wood chips and biochar obtained as a byproduct from a wood gasifier. Three biofilters packed with spruce root wood chips: without biochar (SRWC), a similar one with 10% of biochar (SRWC-B) and that with 10% of biochar impregnated with a nitrogen fertilizer (SRWC-IB) showed similar yet differing maximum elimination capacities of 206 ± 27, 275 ± 21 and 294 ± 20 g m-3 h-1, respectively, enabling high pollutant removal efficiency (>95% at moderate loads) and stable performance. The original biochar adsorption capacity was high (208 ± 6 mgtoluene g-1), but near 70% of it was lost after a 300-day biofilter operation. By contrast, the exposed impregnated biochar drastically increased its adsorption capacity in 300 days (149 ± 7 vs. 17 ± 5 mgtoluene g-1). Colony forming unit (CFU) and microscopic analyses revealed significant packing material colonization by microorganisms and grazing fauna in all three biofilters with an acceptable pressure drop, up to 1020 Pa m-1, at the end of biofilter operation. Despite a higher price (14 vs. 123 €m-3), the application of the best performing SRWC-IB packing can reduce the total investment costs by 9% due to biofilter volume reduction.

• Klíčová slova
• CFM, Packing material, biochar, biofilter, grazing fauna, impregnated biochar, n-butyl acetate, root spruce wood, waste air treatment,
• MeSH
• acetáty * MeSH
• biodegradace MeSH
• dřevěné a živočišné uhlí * MeSH
• filtrace * MeSH
• toluen MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• acetáty * MeSH
• biochar MeSH Prohlížeč
• butyl acetate MeSH Prohlížeč
• dřevěné a živočišné uhlí * MeSH
• toluen MeSH

Background: Multiple sclerosis (MS) is threefold more prevalent in women than men. However, sex-specific efficacy analysis for MS disease-modifying therapies is not typically performed. Methods: Post hoc analyses of data from female patients enrolled in the phase 3, double-blind OPTIMUM study of relapsing MS were carried out. Eligible adults were randomized to ponesimod 20 mg or teriflunomide 14 mg once daily for up to 108 weeks. The primary endpoint was annualized relapse rate (ARR); secondary endpoints included change in symptom domain of Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) at week 108, number of combined unique active lesions (CUALs) per year on magnetic resonance imaging, and time to 12- and 24-week confirmed disability accumulation (CDA). Results: A total of 735 female patients (581 of childbearing potential) were randomized to ponesimod (n = 363, 49.4%) or teriflunomide (n = 372, 50.6%). Relative risk reduction in the ARR for ponesimod versus teriflunomide was 33.1% (mean, 0.192 vs. 0.286, respectively; p < 0.002). Mean difference in FSIQ-RMS for ponesimod versus teriflunomide was -4.34 (0.12 vs. 4.46; p = 0.002); rate ratio in CUALs per year, 0.601 (1.45 vs. 2.41; p < 0.0001), and hazard ratio for time to 12- and 24-week CDA risk estimates, 0.83 (10.7% vs. 12.9%; p = 0.38) and 0.91 (8.8% vs. 9.7%; p = 0.69), respectively. Incidence of treatment-emergent adverse events was similar between treatment groups (89.0% and 90.1%). Conclusions: Analyses demonstrate the efficacy and safety of ponesimod, versus active comparator, for women with relapsing MS, supporting data-informed decision-making for women with MS. Clinical Trial Registration Number: NCT02425644.

• Klíčová slova
• WOCBP, multiple sclerosis, ponesimod, teriflunomide, treatment, women,
• MeSH
• dospělí MeSH
• dvojitá slepá metoda MeSH
• hydroxybutyráty * MeSH
• krotonáty * terapeutické užití   škodlivé účinky   MeSH
• lidé středního věku MeSH
• lidé MeSH
• magnetická rezonanční tomografie MeSH
• nitrily * terapeutické užití   škodlivé účinky   MeSH
• průzkumy a dotazníky MeSH
• relabující-remitující roztroušená skleróza * farmakoterapie   MeSH
• thiazoly škodlivé účinky   terapeutické užití   MeSH
• toluidiny * terapeutické užití   škodlivé účinky   MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze III MeSH
• práce podpořená grantem MeSH
• randomizované kontrolované studie MeSH
• srovnávací studie MeSH
• Názvy látek
• hydroxybutyráty * MeSH
• krotonáty * MeSH
• nitrily * MeSH
• ponesimod MeSH Prohlížeč
• teriflunomide MeSH Prohlížeč
• thiazoly MeSH
• toluidiny * MeSH

BACKGROUND: Teriflunomide is administered orally to treat relapsing-remitting multiple sclerosis. In this prospective pilot study, the free and total serum concentrations of teriflunomide obtained during routine health care were measured and their relationship with disease activity was evaluated. METHODS: Eighty-nine patients were included in this study. Blood samples were collected from April 2021 to February 2022, and free and total teriflunomide serum concentrations were measured. Patient assessment involved monitoring of blood counts and potential adverse effects of teriflunomide. RESULTS: In the steady-state group, total teriflunomide concentrations ranged from 14.7 to 144.2 mg/L, while free concentrations from 31.1 to 389.7 μg/L. In the non-steady-state group, the total concentration ranged from 2.2 to 59.3 mg/L, with free concentrations ranging from 6.8 to 143.5 μg/L. In the steady-state group, a significant inverse correlation was found between absolute peripheral blood lymphocyte count and both total and free teriflunomide serum concentrations. CONCLUSION: Although all patients were treated with the same dose, up to a 10-fold difference in total and free teriflunomide serum concentrations, and up to a 5-fold difference in steady-state trough concentrations were observed. This vast interindividual variability can potentially lead to toxicity or, conversely, to suboptimal therapeutic concentrations of teriflunomide, with the risk of further worsening of multiple sclerosis compensation.

• Klíčová slova
• Concentrations, Multiple sclerosis, Teriflunomide, Therapeutic drug monitoring,
• MeSH
• hydroxybutyráty * MeSH
• krotonáty * MeSH
• lidé MeSH
• nitrily * MeSH
• pilotní projekty MeSH
• prospektivní studie MeSH
• průřezové studie MeSH
• relabující-remitující roztroušená skleróza * farmakoterapie   MeSH
• roztroušená skleróza * farmakoterapie   MeSH
• toluidiny * MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• hydroxybutyráty * MeSH
• krotonáty * MeSH
• nitrily * MeSH
• teriflunomide MeSH Prohlížeč
• toluidiny * MeSH

Endophytic fungi are rich sources of structurally complex chemical scaffolds with interesting biological activities. However, their metabolome is still unknown, making them appealing for novel compound discovery. To maximize the number of secondary metabolites produced from a single microbial source, we used the "OSMAC (one strain-many compounds) approach." In potato dextrose medium, M. phaseolina produced phomeolic acid (1), ergosterol peroxide (2), and a volatile compound 1,4-benzene-diol. Incorporating an epigenetic modifier, sodium valproate, affected the metabolite profile of the fungus. It produced 3-acetyl-3-methyl dihydro-furan-2(3H)-one (3) and methyl-2-(methyl-thio)-butyrate (4), plus volatile chemicals: butylated hydroxy toluene (BHT), di-methyl-formamide, 3-amino-1-propanol, and 1,4-benzenediol, 2-amino-1-(O-methoxyphenyl) propane. The structure of compounds 1-4 was established with the help of spectroscopic data. This study revealed first-time compounds 1-4 in the fungus M. phaseolina using a classical and epigenetic manipulation approach.

• Klíčová slova
• Epigenetics, Filamentous fungi, HDAC inhibitors, OSMAC, Secondary metabolites,
• MeSH
• Ascomycota * metabolismus   MeSH
• benzen metabolismus   MeSH
• Brugmansia * MeSH
• butylhydroxytoluen metabolismus   MeSH
• butyráty metabolismus   MeSH
• endofyty chemie   MeSH
• epigeneze genetická MeSH
• formamidy metabolismus   MeSH
• furany metabolismus   MeSH
• glukosa metabolismus   MeSH
• kyselina valproová metabolismus   MeSH
• propan metabolismus   MeSH
• toluen metabolismus   MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• benzen MeSH
• butylhydroxytoluen MeSH
• butyráty MeSH
• formamidy MeSH
• furany MeSH
• glukosa MeSH
• kyselina valproová MeSH
• propan MeSH
• toluen MeSH

BACKGROUND: The monoclonal antibody ublituximab enhances antibody-dependent cellular cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of relapsing multiple sclerosis. METHODS: In two identical, phase 3, double-blind, double-dummy trials (ULTIMATE I and II), participants with relapsing multiple sclerosis were randomly assigned in a 1:1 ratio to receive intravenous ublituximab (150 mg on day 1, followed by 450 mg on day 15 and at weeks 24, 48, and 72) and oral placebo or oral teriflunomide (14 mg once daily) and intravenous placebo. The primary end point was the annualized relapse rate. Secondary end points included the number of gadolinium-enhancing lesions on magnetic resonance imaging (MRI) by 96 weeks and worsening of disability. RESULTS: A total of 549 participants were enrolled in the ULTIMATE I trial, and 545 were enrolled in the ULTIMATE II trial; the median follow-up was 95 weeks. In the ULTIMATE I trial, the annualized relapse rate was 0.08 with ublituximab and 0.19 with teriflunomide (rate ratio, 0.41; 95% confidence interval [CI], 0.27 to 0.62; P<0.001); in the ULTIMATE II trial, the annualized relapse rate was 0.09 and 0.18, respectively (rate ratio, 0.51; 95% CI, 0.33 to 0.78; P = 0.002). The mean number of gadolinium-enhancing lesions was 0.02 in the ublituximab group and 0.49 in the teriflunomide group (rate ratio, 0.03; 95% CI, 0.02 to 0.06; P<0.001) in the ULTIMATE I trial and 0.01 and 0.25, respectively (rate ratio, 0.04; 95% CI, 0.02 to 0.06; P<0.001), in the ULTIMATE II trial. In the pooled analysis of the two trials, 5.2% of the participants in the ublituximab group and 5.9% in the teriflunomide group had worsening of disability at 12 weeks (hazard ratio, 0.84; 95% CI, 0.50 to 1.41; P = 0.51). Infusion-related reactions occurred in 47.7% of the participants in the ublituximab group. Serious infections occurred in 5.0% in the ublituximab group and in 2.9% in the teriflunomide group. CONCLUSIONS: Among participants with relapsing multiple sclerosis, ublituximab resulted in lower annualized relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not result in a significantly lower risk of worsening of disability. Ublituximab was associated with infusion-related reactions. (Funded by TG Therapeutics; ULTIMATE I and II ClinicalTrials.gov numbers, NCT03277261 and NCT03277248.).

• MeSH
• antiflogistika nesteroidní terapeutické užití   MeSH
• dvojitá slepá metoda MeSH
• gadolinium terapeutické užití   MeSH
• hydroxybutyráty MeSH
• imunosupresiva terapeutické užití   MeSH
• krotonáty MeSH
• lidé MeSH
• magnetická rezonanční tomografie MeSH
• monoklonální protilátky * terapeutické užití   MeSH
• nitrily MeSH
• relabující-remitující roztroušená skleróza * komplikace   diagnostické zobrazování   farmakoterapie   patologie   MeSH
• roztroušená skleróza komplikace   diagnostické zobrazování   farmakoterapie   patologie   MeSH
• toluidiny MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze III MeSH
• randomizované kontrolované studie MeSH
• Názvy látek
• antiflogistika nesteroidní MeSH
• gadolinium MeSH
• hydroxybutyráty MeSH
• imunosupresiva MeSH
• krotonáty MeSH
• monoklonální protilátky * MeSH
• nitrily MeSH
• teriflunomide MeSH Prohlížeč
• toluidiny MeSH
• ublituximab MeSH Prohlížeč

Autoerotic asphyxia is a form of deviant sexual behavior that seeks sexual gratification by means of manipulation with one's own body resulting in asphyxia, and may sometimes turn out to be fatal. Autoerotic fatalities involving autoerotic asphyxia are divided into two groups: "typical" autoerotic fatalities involve mechanical compression of the neck, chest or abdomen, whereas "atypical" autoeroticism involves sexual self-stimulation by other means. Cases where asphyxiophilic behavior is accompanied by volatile substance abuse are reported to be rather rare, but may involve a high risk of fatal results. This paper presents a case of accidental "atypical" autoeroticism involving victim's abuse of toluene, which, combined with asphyxiophilic airway occlusion, led to death. For the sake of comprehensiveness, both a verbal description and a schematic representation of the major metabolic pathways of acute and chronic abuse metabolic markers is provided.

• Klíčová slova
• Autoerotic asphyxia, Autoerotic death, Death scene investigation, Intoxication, Toluene, Volatile substances,
• MeSH
• asfyxie etiologie   MeSH
• lidé MeSH
• parafilie * komplikace   MeSH
• poruchy spojené s užíváním psychoaktivních látek * komplikace   MeSH
• sexuální chování MeSH
• toluen MeSH
• úrazy a nehody MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH
• Názvy látek
• toluen MeSH

Nitrated monoaromatic hydrocarbons (NMAHs) are ubiquitous in the environment and an important part of atmospheric humic-like substances (HULIS) and brown carbon. They are ecotoxic and with underresearched toxic potential for humans. NMAHs were determined in size-segregated ambient particulate matter collected at two urban sites in central Europe, Ostrava and Kladno, Czech Republic. The average sums of 12 NMAHs (Σ12NMAH) measured in winter PM10 samples from Ostrava and Kladno were 102 and 93 ng m-3, respectively, and 8.8 ng m-3 in summer PM10 samples from Ostrava. The concentrations in winter corresponded to 6.3-7.3% and 2.6-3.1% of HULIS-C and water-soluble organic carbon (WSOC), respectively. Nitrocatechols represented 67-93%, 61-73% and 28-96% of NMAHs in PM10 samples collected in winter and summer at Ostrava and in winter at Kladno, respectively. The mass size distribution of the targeted substance classes peaked in the submicrometre size fractions (PM1), often in the PM0.5 size fraction especially in summer. The bioaccessible fraction of NMAHs was determined by leaching PM3 samples in two simulated lung fluids, Gamble's solution and artificial lysosomal fluid (ALF). More than half of NMAH mass is found bioaccessible, almost complete for nitrosalicylic acids. The bioaccessible fraction was generally higher when using ALF (mimics the chemical environment created by macrophage activity, pH 4.5) than Gamble's solution (pH 7.4). Bioaccessibility may be negligible for lipophilic substances (i.e. log KOW > 4.5).

• Klíčová slova
• Aerosol, Air pollution, Bioaccessibility, Nitroaromatic compounds,
• MeSH
• dusičnany MeSH
• dusíkaté sloučeniny MeSH
• katecholy MeSH
• látky znečišťující vzduch * analýza   MeSH
• lidé MeSH
• monitorování životního prostředí MeSH
• nitrofenoly MeSH
• pevné částice * analýza   MeSH
• toluen MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• dusičnany MeSH
• dusíkaté sloučeniny MeSH
• katecholy MeSH
• látky znečišťující vzduch * MeSH
• nitrocatechol MeSH Prohlížeč
• nitrofenoly MeSH
• pevné částice * MeSH
• toluen MeSH